TX-PLANVIEW
21.5.2020 16:02:05 CEST | Business Wire | Press release
Planview® today announced it has ranked highest for both the Single Lean/Kanban Team and Scaled Agile Framework® (SAFe) Use Cases in the Gartner “Critical Capabilities for Enterprise Agile Planning Tools*” report. The research assessed 16 enterprise Agile planning tool offerings across six use cases. In addition to receiving the highest score in the Single Lean/Kanban Team and SAFe Use Cases, Planview received the second highest scores in the Distributed Agile and the Project and Program Portfolio Use Cases.
“The key to success in any Agile transformation is leveraging solutions that empower your teams at every stage of the journey,” said Patrick Tickle, Planview Chief Product Officer. “We’re pleased to be recognized by Gartner for the Single Lean/Kanban Team and SAFe Use Cases. We believe these two methods are at the core of today’s transformations – scaling with SAFe and the accelerating use of Kanban to support continuous delivery and business agility.”
In today’s fast-paced, highly disruptive markets, teams must leverage a variety of work methodologies and processes to get work done, such as Lean, Agile, Scrum, Kanban, Scrumban, and traditional project delivery. Planview’s full spectrum of Portfolio and Work Management solutions help enterprises transform strategy to delivery. In particular, Planview’s approach to Enterprise Kanban ensures organizations, from the Agile teams to the business, can continue to deliver value quickly and effectively, without giving up visibility and management to broader strategic outcomes.
Planview was also recently recognized as a Leader in the 2020 Gartner Magic Quadrant for Enterprise Agile Planning Tools **, which positioned the company as highest on the ability to execute axis. The 2020 Gartner Critical Capabilities for Enterprise Agile Planning Tools research complements the companion 2020 Gartner Magic Quadrant for Enterprise Agile Planning Tools, and looks at product capabilities and how those capabilities can be applied to use cases.
To learn more about the Planview Lean and Agile Delivery Solution visit: planview.com/lean-agile-delivery .
Additional Resources:
- Blog: Lean into the Changing World of Work
- Guide: The Ultimate Lean and Agile Software Solution Buyer’s Guide
- Whitepaper: 7 Benefits of Scaling Agile
- 3 Minute Pathfinder: Lean-Agile Pathfinder
- Follow the Planview Blog
- Connect with Planview on Twitter , Facebook and LinkedIn
*Gartner, Critical Capabilities for Enterprise Agile Planning Tools by Mike West, Keith Mann, Bill Blosen, Akis Sklavounakis, Deacon D.K Wan, April 29, 2020
**Gartner, Magic Quadrant for Enterprise Agile Planning Tools by Keith Mann, Mike West, Bill Blosen, Akis Sklavounakis, Deacon D.K Wan, April 21, 2020
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions uniquely help organizations navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit https://www.planview.com/ .
Planview and the Planview logo are registered trademarks of Planview, Inc. All other trademarks are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005447/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom